GlassScriptPhysician profile
Alexander Marzuka
NPI 1447661939
$13,538.52
in general payments reported to CMS, 2019-2025
35 companies · $1,423 in 2025
The $1,423 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,382 · 2020: $576 · 2021: $2,202 · 2022: $2,567 · 2023: $2,205 · 2024: $2,184 · 2025: $1,423.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,505 · Education: $308.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,504.64 |
| Education | $307.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,988.13 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,780.80 | 2019-2025 | Aklief, Oracea, Epsolay |
| Janssen Biotech, INC. | $1,552.94 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $940.33 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $900.07 | 2019-2025 | Dupixent |
| Lilly USA, LLC | $809.57 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $701.32 | 2019-2025 | |
| Incyte Corporation | $553.32 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $519.90 | 2019-2025 | Adbry |
| Biofrontera INC. | $508.89 | 2019 | |
| Amgen INC. | $413.77 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $333.17 | 2019-2024 | Winlevi, Absorica Ld |
| Allergan, INC. | $297.98 | 2019-2022 | |
| Pfizer INC. | $250.15 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $247.60 | 2023-2025 | Zoryve |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $227.75 | 2024-2025 | Daxxify |
| E.R. Squibb & Sons, L.L.C. | $192.05 | 2022-2025 | Sotyktu |
| Almirall LLC | $173.37 | 2019-2023 | Klisyri |
| Ucb, INC. | $146.89 | 2020-2023 | Cimzia |
| Vyne Pharmaceuticals INC. | $121.72 | 2020-2021 | |
| Merz North America, INC. | $115.59 | 2019-2022 | |
| Epi Health, LLC | $102.26 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $100.85 | 2019-2023 | |
| Dermavant Sciences, INC. | $99.43 | 2022-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $95.81 | 2019-2024 | Jublia, Cabtreo, Arazlo |
| Hill Dermaceuticals, INC. | $89.45 | 2021 | |
| Celgene Corporation | $84.17 | 2019 | |
| Journey Medical Corporation | $36.67 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.99 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $27.47 | 2020-2021 | |
| Organon LLC | $25.78 | 2025 | Vtama |
| Taro Pharmaceuticals USA, INC. | $22.67 | 2019 | |
| Genentech USA, INC. | $21.44 | 2022 | |
| Sebela Pharmaceuticals INC. | $14.98 | 2019 | |
| Mission Pharmacal Company | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Marzuka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.